Literature DB >> 33231286

Detection of SARS-CoV-2 in a case of DRESS by sulfasalazine: could there be a relationship with clinical importance?

Sindy N Balconi1, Natane T Lopes2, Laura Luzzatto1, Renan R Bonamigo1,2,3.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2020        PMID: 33231286      PMCID: PMC7753828          DOI: 10.1111/ijd.15316

Source DB:  PubMed          Journal:  Int J Dermatol        ISSN: 0011-9059            Impact factor:   2.736


× No keyword cloud information.
Dear Editor, Drug reaction with eosinophilia and systemic symptoms (DRESS) is a hypersensitivity syndrome that includes severe skin rash, fever, lymphadenopathy, hematologic changes with eosinophilia, atypical lymphocytes, and possible involvement of other organs, such as liver and kidneys. It’s a potentially life‐threatening condition that usually appears within 2 months of initiation of a new drug. , Diagnosis relies on clinical and laboratory findings and on use of the RegiSCAR scoring system. , There is evidence that the disease occurs in genetically predisposed people after ingestion of a related drug, such as sulfonamides. Reactivation of some viruses and the immunological response that follows it are involved mechanisms. We report a case of DRESS associated with COVID‐19. A 20‐year‐old woman presented to the emergency department with a morbilliform, erythematous‐violaceous rash, fever (38.5 °C), lymphadenopathy, pruritus, myalgia, and arthralgia that started 14 days after initiation of sulfasalazine treatment for ulcerative colitis. Exanthema appeared on her face and spread to the trunk and upper and lower extremities (with follicular accentuation—Fig. 1) 4 days before admission, when she stopped sulfasalazine on her own. A nasopharyngeal swab was collected for PCR for SARS‐CoV‐2, a routine hospital procedure because of local epidemic. The test was positive.
Figure 1

Erythematous‐violaceous rash, with follicular accentuation (above). Histopathology (hematoxylin and eosin, ×200): vacuolar degeneration of the basal layer, lymphoid infiltrate in the dermo‐epidermal interface (below)

Erythematous‐violaceous rash, with follicular accentuation (above). Histopathology (hematoxylin and eosin, ×200): vacuolar degeneration of the basal layer, lymphoid infiltrate in the dermo‐epidermal interface (below) The symptoms became more severe, with worsening liver function, lip erosion, facial and acral edema, purple macules in the plantar regions, and digital pulps (resembling chilblain‐like acral lesions) (Fig. 2).
Figure 2

Facial erythema and edema (left). Digital pulps: erythema‐purpuric macules (right)

Facial erythema and edema (left). Digital pulps: erythema‐purpuric macules (right) Blood tests showed significant leukocytosis (28,020/μl), lymphocytosis (9,807/μl), 13% of atypical lymphocytes, eosinophilia (2,522/μl), elevated lactate dehydrogenase (1,378 U/l), and elevated erythrocyte sedimentation rate, C‐reactive protein, and D‐dimers (1,440 ng/ml). Transaminase levels were elevated to 7‐fold the upper limit of normal (ALT 403 iU/l and AST 350 iU/l). Antinuclear antibodies, blood cultures, and serologic test results for HIV, HCV, HBV, toxoplasmosis, syphilis, CMV, and EBV were negative. Histopathology of the rash revealed spongiosis, intense vacuolar degeneration of the basal layer and lymphoid infiltrate in the dermo‐epidermal interface, and presence of rare eosinophils, without vasculitis (Fig 1). Based on clinical, laboratory, and histopathologic features and a RegiSCAR score >5, both DRESS and COVID‐19 were diagnosed. Numerous skin rashes have been reported in SARS‐CoV‐2 infection. In the present case, the patient had concurrent diagnoses of DRESS and COVID‐19. Supportive and corticosteroid therapy was performed, and she recovered and was discharged. Up to 60% of patients with DRESS have evidence of simultaneous viral infection and, considering the current state of knowledge about drug–virus interaction, there is a high possibility that strong drug reactions of type IVc and IVd may reactivate viruses. Paradoxical worsening of symptoms in DRESS has been the subject of recent studies. Although there is no consensus, a relationship between the disease and viral reactivation has been suggested to contribute to higher severity, especially reactivation of viruses belonging to the Betaherpesvirinae subfamily (HHV‐6, EBV, HHV‐7, and CMV). , However, according to Rojeau and Dupin, it is possible that the severity of DRESS caused by viral reactivation is related to other individual factors, particularly a preserved immune system. Regarding the pathomechanism of DRESS and COVID‐19 coexistence, it is important to remember the high‐serum TNF‐α levels in patients with DRESS and viral reactivation, suggesting that TNF‐α might play an important role in viral reactivation and disease worsening. Also, patients with DRESS and viral infection displayed a decreased number of plasmacytoid dendritic cells (pDCs) in circulation and accumulation in the skin. The pDCs play a key role in the response to viral infection by producing cytokines such as IFN‐γ, and available data show that IFN‐γ produced by pDCs, as well as related inflammatory cytokines, play a protective role against COVID‐19. The subject of DRESS and viral reactivations remains with non‐definitive conclusions, and this report adds a new topic: SARS‐CoV‐2 infection in the current pandemic.
  5 in total

1.  Virus Reactivation in Drug Reaction with Eosinophilia and Systemic Symptoms (Dress) Results from a Strong Drug-Specific Immune Response.

Authors:  Jean-Claude Roujeau; Nicolas Dupin
Journal:  J Allergy Clin Immunol Pract       Date:  2017 May - Jun

Review 2.  Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS): An Interplay among Drugs, Viruses, and Immune System.

Authors:  Yung-Tsu Cho; Che-Wen Yang; Chia-Yu Chu
Journal:  Int J Mol Sci       Date:  2017-06-09       Impact factor: 5.923

Review 3.  Recent Advances in Drug-Induced Hypersensitivity Syndrome/Drug Reaction with Eosinophilia and Systemic Symptoms.

Authors:  Hideaki Watanabe
Journal:  J Immunol Res       Date:  2018-03-18       Impact factor: 4.818

Review 4.  Cutaneous manifestations in patients with COVID-19: a preliminary review of an emerging issue.

Authors:  A V Marzano; N Cassano; G Genovese; C Moltrasio; G A Vena
Journal:  Br J Dermatol       Date:  2020-07-05       Impact factor: 11.113

Review 5.  Should we stimulate or suppress immune responses in COVID-19? Cytokine and anti-cytokine interventions.

Authors:  Yvan Jamilloux; Thomas Henry; Alexandre Belot; Sébastien Viel; Maxime Fauter; Thomas El Jammal; Thierry Walzer; Bruno François; Pascal Sève
Journal:  Autoimmun Rev       Date:  2020-05-04       Impact factor: 9.754

  5 in total
  3 in total

1.  Benralizumab: a potential tailored treatment for life-threatening DRESS in the COVID-19 era.

Authors:  Farah Mesli; Maëlle Dumont; Angèle Soria; Matthieu Groh; Matthieu Turpin; Guillaume Voiriot; Cedric Rafat; Delphine Staumont Sallé; Aude Gibelin; Cyrielle Desnos
Journal:  J Allergy Clin Immunol Pract       Date:  2021-07-14

2.  Cutaneous and systemic hyperinflammation drives maculopapular drug exanthema in severely ill COVID-19 patients.

Authors:  Yasutaka Mitamura; Daniel Schulz; Saskia Oro; Nick Li; Isabel Kolm; Claudia Lang; Reihane Ziadlou; Ge Tan; Bernd Bodenmiller; Peter Steiger; Angelo Marzano; Nicolas de Prost; Olivier Caudin; Mitchell Levesque; Corinne Stoffel; Peter Schmid-Grendelmeier; Emanual Maverakis; Cezmi A Akdis; Marie-Charlotte Brüggen
Journal:  Allergy       Date:  2021-07-19       Impact factor: 14.710

3.  Does sensitization by SARS-CoV-2 immune complexes trigger DRESS syndrome?

Authors:  Virgínia Barbeitos Cruz; Luiz Fernando Fróes Fleury Júnior; Christiane Reis Kobal; Nilzio Antonio da Silva
Journal:  Braz J Infect Dis       Date:  2022-02-28       Impact factor: 3.257

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.